Studies have reported that shikonin can significantly prevent the loss of E-cadherin in diabetic nephropathy (DN) mice, attenuate the expression of TGF-β1-induced mesenchymal markers, and inhibit TGF-β1/Smad-mediated EMT (Li Z. et al., 2018). This evidence concerns the gene TGFB1 and liver dysplastic nodule.